Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...